US FDA tightens regulations for use of erythopoiesis-stimulating agents

被引：0
作者：
不详
机构：
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：483 / 483
页数：1
相关论文
共 50 条
[41]   THE FDA BLACK BOX WARNING DOES REDUCE THE USE OF ERYTHROPOIETIN STIMULATING AGENTS AND INCREASES BLOOD TRANSFUSIONS IN INSURED, LOW INCOME CANCER PATIENTS [J].
Noxon, V ;
Bennett, C. ;
Wu, J. .
VALUE IN HEALTH, 2014, 17 (07) :A655-A655
[42]   The Use of Erythropoiesis-Stimulating Agents in the Intensive Care Unit [J].
Piagnerelli, Michael ;
Vincent, Jean-Louis .
CRITICAL CARE CLINICS, 2012, 28 (03) :345-+
[43]   Use and cost of erythropoiesis-stimulating agents in patients with cancer [J].
Daniel, Gregory ;
Hurley, Dana ;
Whyte, Joanna L. ;
Willey, Vincent ;
Wilson, Marcus ;
Kallich, Joel .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) :1775-1784
[44]   Use of erythropoiesis-stimulating agents in obese hemodialysis patients [J].
Park, Sun-Hee .
KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (03) :308-309
[45]   Clinical use of erythropoiesis-stimulating agents: defining the benefits [J].
Pirker, Robert .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) :S153-S155
[46]   Anemia Management in CKD Patients in the Era of New US Food and Drug Administration Recommendations on the Use of Erythropoiesis-Stimulating Agents [J].
Kaufman, James S. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (02) :191-193
[47]   HHS, USDA Establish New Regulations for Use of Select Biological Agents [J].
Moshe Shalev .
Lab Animal, 2003, 32 (2) :15-16
[48]   Understanding intravenous iron utilization post CMS PPS and FDA label revision for erythropoiesis stimulating agents [J].
Bacchus, Shaffeeulah .
PHARMACOTHERAPY, 2014, 34 (06) :E99-E99
[49]   Ramucirumab receives US FDA approval for use in advanced stomach cancer [J].
Brown, Emily .
FUTURE ONCOLOGY, 2014, 10 (08) :1340-1340
[50]   US FDA approves use of genetic testing to estimate warfarin dose [J].
Reactions Weekly, 2007, 1166 (1) :3-3
12345